Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 4, 2002, Pages 336-341

  Iyer, Lalitha ^a,b,c   Ramírez, Jacqueline ^a,b,c   Shepard, Dale R ^a,b,c   Bingham, Christopher M ^a,b,c   Hossfeld, Dieter Kurt ^a,b,c   Ratain, Mark J ^a,b,c   Mayer, Ulrich ^a,b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c SRI INTERNATIONAL   (United States)

Author keywords

CPT 11; Irinotecan; P glycoprotein; PSC833; Transporters

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DRUG METABOLITE; DRUG VEHICLE; GLYCOPROTEIN P; IRINOTECAN; UNCLASSIFIED DRUG; VALSPODAR;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG EXCRETION; DRUG POTENCY; DRUG TRANSPORT; FEMALE; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; FEMALE; GLUCURONIDES; MICE; P-GLYCOPROTEIN;

EID: 0036207164     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0420-4     Document Type: Article

References (30)

1. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT- 11
2. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
3. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane
4. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter
5. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irino-tecan and its metabolites in rats
6. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats
7. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
8. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
9. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
10. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
11. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
12. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
13. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin] by human hepatic microsomes
14. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
15. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
16. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
17. UGTIAI*2 polymorphism as a determinant of irinotecan disposition and toxicity
18. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
19. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine
20. Irinotecan (CPT-11) metabolites in human bile and urine
21. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
22. A phase I study of CPT-11 with pharmacokinetic modulation by cyclosporine A and phenobarbital
23. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hy-droxycamptothecin (SN-38), by human liver carboxylesterase
24. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
25. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications
26. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
27. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
28. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
29. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
30. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs